{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:45:25Z","timestamp":1791135925179,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1857,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1111\/j.1399-3062.2010.00504.x","type":"journal-article","created":{"date-parts":[[2010,5,12]],"date-time":"2010-05-12T02:11:25Z","timestamp":1273630285000},"page":"322-329","source":"Crossref","is-referenced-by-count":151,"title":["Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy"],"prefix":"10.1111","volume":"12","author":[{"given":"B.","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gilroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ratnamohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kerridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hertzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Bradstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,20]]},"reference":[{"issue":"(3","key":"10.1111\/j.1399-3062.2010.00504.x-BIB1|cit1","first-page":"280","article-title":"CMV antigenemia following bone marrow transplantation","volume":"6","author":"Osarogiagbon","year":"2000","journal-title":"risk factors and outcomes"},{"issue":"(S","key":"10.1111\/j.1399-3062.2010.00504.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1038\/bmt.2008.120","article-title":"CMV infections after hematopoietic stem cell transplantation","volume":"42","author":"Ljungman","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"(1","key":"10.1111\/j.1399-3062.2010.00504.x-BIB3|cit3","first-page":"13","article-title":"CMV infection in bone marrow and solid organ transplant patients in the era of antiviral prophylaxis","volume":"7","author":"Hebart","year":"2001","journal-title":"Herpes"},{"key":"10.1111\/j.1399-3062.2010.00504.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1086\/342883","article-title":"Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation","volume":"35","author":"Zaia","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1399-3062.2010.00504.x-BIB5|cit5","first-page":"4063","article-title":"Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation","volume":"88","author":"Boeckh","year":"1996","journal-title":"a randomized double-blind study"},{"issue":"(3","key":"10.1111\/j.1399-3062.2010.00504.x-BIB6|cit6","first-page":"209","article-title":"Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products","volume":"11","author":"Rubie","year":"1993","journal-title":"Bone Marrow Transplant"},{"issue":"(6","key":"10.1111\/j.1399-3062.2010.00504.x-BIB7|cit7","first-page":"507","article-title":"CMV infections following allogeneic BMT","volume":"77","author":"Bacigalupo","year":"1992","journal-title":"risk factors, early treatment and correlation with transplant related mortality"},{"issue":"(3","key":"10.1111\/j.1399-3062.2010.00504.x-BIB8|cit8","first-page":"401","article-title":"Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group","volume":"16","author":"Atkinson","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"(6","key":"10.1111\/j.1399-3062.2010.00504.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2003-10-3616","article-title":"The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy","volume":"103","author":"Boeckh","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1399-3062.2010.00504.x-BIB10|cit10","first-page":"273","article-title":"High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors","volume":"185","author":"Nichols","year":"2002","journal-title":"evidence for indirect effects of primary CMV infection"},{"key":"10.1111\/j.1399-3062.2010.00504.x-BIB11|cit11","first-page":"2219","article-title":"Unrelated donor marrow transplantation for chronic myelogenous leukemia","volume":"95","author":"McGlave","year":"2000","journal-title":"9 years' experience of the national marrow donor program"},{"key":"10.1111\/j.1399-3062.2010.00504.x-BIB12|cit12","first-page":"1162","article-title":"Cytomegalovirus infection after bone marrow transplantation","volume":"67","author":"Miller","year":"1986","journal-title":"an association with acute graft-v-host disease"},{"issue":"(1","key":"10.1111\/j.1399-3062.2010.00504.x-BIB13|cit13","first-page":"78","article-title":"Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation","volume":"91","author":"Ljungman","year":"2006","journal-title":"Haematologica"},{"issue":"(6","key":"10.1111\/j.1399-3062.2010.00504.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1182\/blood.V99.6.1978","article-title":"Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study","volume":"99","author":"Junghanss","year":"2002","journal-title":"Blood"},{"issue":"(7","key":"10.1111\/j.1399-3062.2010.00504.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/sj.bmt.1704164","article-title":"Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia","volume":"32","author":"Schetelig","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"(8","key":"10.1111\/j.1399-3062.2010.00504.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/sj.bmt.1705974","article-title":"Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation","volume":"41","author":"Hill","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"(1","key":"10.1111\/j.1399-3062.2010.00504.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00277-003-0706-1","article-title":"Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation","volume":"82","author":"Nachbaur","year":"2003","journal-title":"Ann Hematol"},{"issue":"(8","key":"10.1111\/j.1399-3062.2010.00504.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ajh.21215","article-title":"Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors","volume":"83","author":"Chae","year":"2008","journal-title":"Am J Hematol"},{"issue":"(1","key":"10.1111\/j.1399-3062.2010.00504.x-BIB19|cit19","first-page":"4357","article-title":"High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation","volume":"99","author":"Chakrabarti","year":"2002","journal-title":"potential role of Campath-1H in delaying immune reconstitution"},{"issue":"(1","key":"10.1111\/j.1399-3062.2010.00504.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/sj.bmt.1703583","article-title":"Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation","volume":"29","author":"Hambach","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"(4","key":"10.1111\/j.1399-3062.2010.00504.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1046\/j.1365-2141.2003.04671.x","article-title":"Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation","volume":"123","author":"Junghanss","year":"2003","journal-title":"Br J Haematol"},{"issue":"(9","key":"10.1111\/j.1399-3062.2010.00504.x-BIB22|cit22","first-page":"1106","article-title":"Cytomegalovirus infection after allogeneic transplantation","volume":"13","author":"Walker","year":"2007","journal-title":"comparison of cord blood with peripheral blood and marrow graft sources"},{"issue":"(1","key":"10.1111\/j.1399-3062.2010.00504.x-BIB23|cit23","first-page":"5403","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients","volume":"111","author":"Winston","year":"2008","journal-title":"a multicenter, randomized, double-blind, placebo controlled, dose-ranging study"},{"issue":"(6","key":"10.1111\/j.1399-3062.2010.00504.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbmt.2007.02.004","article-title":"Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Micklethwaite","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"(1","key":"10.1111\/j.1399-3062.2010.00504.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2008-06-161695","article-title":"Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation","volume":"112","author":"Micklethwaite","year":"2008","journal-title":"Blood"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-3062.2010.00504.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1399-3062.2010.00504.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T01:29:08Z","timestamp":1625621348000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-3062.2010.00504.x"}},"subtitle":["CMV reactivation in HSCT"],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1399-3062.2010.00504.x","relation":{},"ISSN":["1398-2273"],"issn-type":[{"value":"1398-2273","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}